Clinical Trials Logo

Filter by:
NCT ID: NCT03298958 Withdrawn - Bladder Cancer Clinical Trials

Secondary Prevention Trial of Rapamycin in Patients With Resected Non-muscle Invasive Bladder Cancer

Start date: November 1, 2018
Phase: Phase 3
Study type: Interventional

The study is a multi-site Phase 3 double-blinded randomized placebo-controlled trial. Subjects are randomly assigned to receive either a placebo or oral Sirolimus: 0.5 mg daily. All subjects will be treated for 2 years or until disease recurrence. Patients will undergo endoscopic evaluation of the bladder every 3 months for the first 2 years following enrollment and then every 6 months for an additional 2 years on study. Selection of BCG immune therapy is at the discretion of the treating urologist but in general is reserved for high-risk patients. Patients concurrently receiving BCG immune therapy will receive standard BCG therapy including induction (weekly for 6 weeks) and maintenance (weekly for 3 weeks at 3 months, 6 months, and then every 6 months following tumor resection).

NCT ID: NCT03297554 Withdrawn - Childhood Obesity Clinical Trials

Healthy Kids Pilot

Start date: November 13, 2017
Phase: N/A
Study type: Interventional

Up to 30 parent/child dyads will be recruited to participate in an m-Health intervention (delivered over smartphone, iPad/Tablet, or desktop/laptop) to promote healthy behaviors and healthy weight among children and their parents.

NCT ID: NCT03297463 Withdrawn - Metastatic Melanoma Clinical Trials

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

Start date: January 31, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1b/2 study designed to evaluate combination of the human T-cell cytokine Interleukin-2 (IL-2) and a checkpoint inhibitor Ipilimumab immediately following a course of hypofractionated palliative radiation therapy in the management of unresectable, relapsed/refractory metastatic melanoma.

NCT ID: NCT03296124 Withdrawn - Prostate Cancer Clinical Trials

Prognostic Value of Androgen Receptor Expression and Mutations Within Oncogenes and Tumor Suppressor Genes in Patients Treated for High Risk Prostate Cancer With Proton Therapy (PRX32)

PRX32
Start date: December 7, 2017
Phase:
Study type: Observational

Retrospective Review Study for Prognostic Transcriptional Output Related to Androgen Receptor Expression in Patients Treated for High Risk Prostate Cancer with Proton Therapy

NCT ID: NCT03295695 Withdrawn - Breast Cancer Clinical Trials

PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient

Start date: December 2020
Phase: Early Phase 1
Study type: Interventional

This is a single arm, phase 0 study to evaluate the safety and efficacy of PET-CT scans with FDG-labeled RBC in patients with breast cancer. Cardiac ejection fraction can be calculated and monitored in breast cancer patients during chemotherapy using a FDG-RBC PET-CT scan. The purpose of this study is to determine if calculated cardiac ejection fraction shows high concordance with results from echocardiography.

NCT ID: NCT03295656 Withdrawn - Appendicitis Acute Clinical Trials

Contrast-Enhanced Ultrasound Diagnosis of Acute Appendicitis

Start date: July 15, 2020
Phase: Phase 1
Study type: Interventional

This study evaluates the ability of contrast-enhanced ultrasound to improve the diagnosis of acute appendicitis in children compared to conventional ultrasound.

NCT ID: NCT03293927 Withdrawn - Delirium Clinical Trials

Polypharmacy-related Adverse Events in Critically Ill Children

Start date: April 9, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to learn how 2 medications (fentanyl and dexmedetomidine) affect how sick children think and interact with their environments.

NCT ID: NCT03292679 Withdrawn - Facial Fracture Clinical Trials

Craniofacial Applications of 3D Printing

Start date: June 2019
Phase:
Study type: Observational [Patient Registry]

3D printing is a technology that allows for physical creation of a 3D model (usually made of plastic) based on computer generated 3D images from CT scans. The 3D images of craniofacial skeleton using computer software are routinely generated and, in turn, these 3D images can be used to create a plastic 3D model using a 3D printer. Unstable or comminuted facial fractures need to be reduced and rigidly fixated using titanium plates and screws. Bending and shaping of the plates is usually performed by free-hand based on the surgeon's estimation of what best fits the fracture. Often, bending the titanium plates to the shape of pre-injury skeletal contour is difficult when the bone is fractured into many pieces or is unstable, or when the patient is edentulous (missing several teeth). The process can increase the time spent in surgery and the bent plates may not snugly fit the fracture. For these difficult cases, one option is to use commercially manufactured 3D printed patient-specific models. The patient-specific models provide the benefit of correct shape / form for increased surgical accuracy, and decreased intra-operative time. However these commercial models are manufactured at distant facilities and usually require more than 7 days before delivery. As such, they delay time to surgery and cannot be used for urgent surgery. Additionally, the commercially manufactured implants are expensive, significantly increasing the cost of treatment. The purpose of this study is to explore whether custom plastic models 3D printed at Shock Trauma Center and used for bending and shaping plates for facial fracture repair can improve results of facial fracture reconstruction. Our plastic surgery division will design and produce facial bone 3D model of patients (with facial fractures) using an in-house 3D printer, then use the 3D model to contour the hardware pre-op or intra-op at the time of fracture repair. We believe that we can achieve better repair, shorter surgery time, and save hardware cost.

NCT ID: NCT03291353 Withdrawn - Clinical trials for Refractory Acute Myeloid Leukemia

Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute Myeloid Leukemia

Start date: October 17, 2017
Phase: Early Phase 1
Study type: Interventional

This is an open label, single-arm, pilot trial to evaluate the immune effects, safety and tolerability of pembrolizumab in subjects newly diagnosed with acute myeloid leukemia (AML) who have persistent leukemia after induction chemotherapy. Patients must have an ECOG performance status of 0-1. The enrollment target for this study is 10 patients.

NCT ID: NCT03290963 Withdrawn - Clinical trials for Treatment Resistant Depression

Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine

Start date: November 30, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to compare the antidepressant effect of lithium versus placebo in adults receiving ketamine. Lithium is available commercially for depression; ketamine is available commercially and can help the symptoms of depression; however, it has not been approved by the U.S. Food and Drug Administration (FDA) for this use. The FDA has allowed the use of this drug in this research study.